

## Original article

# Ultrafiltration rate adjusted to body weight and mortality in hemodialysis patients<sup>☆</sup>

Raul Fernandez-Prado<sup>\*</sup>, Jessy Korina Peña-Esparragoza, Begoña Santos-Sánchez-Rey, Mónica Pereira, Alejandro Avello, Elena Gomá-Garcés, Marina González-Rivera, Guillermo González-Martin, Carolina Gracia-Iguacel, Ignacio Mahillo, Alberto Ortiz, Emilio González-Parra

Hospital Fundación Jiménez Díaz, Madrid, Spain

## ARTICLE INFO

## Article history:

Received 15 June 2020

Accepted 17 October 2020

Available online 3 November 2021

## Keywords:

Hemodialysis

Mortality

Ultrafiltration rate

## ABSTRACT

**Background and aims:** Mortality among hemodialysis patients remains high. An elevated ultrafiltration rate adjusted by weight (UFR/W) has been associated with hypotension and higher risk of death and/or cardiovascular events.

**Methods:** We evaluated the association between UFR/W and mortality in 215 hemodialysis patients. The mean follow-up was  $28 \pm 6.12$  months. We collected patients' baseline characteristics and mean UFR/W throughout the follow-up.

**Results:** Mean UFR/W was  $9.0 \pm 2.4$  and tertiles 7.1 y 10.1 mL/kg/h. We divided our population according to the percentage of sessions with UFR/W above the limits described in the literature associated with increased mortality (10.0 mL/kg/h and 13.0 mL/kg/h). Patients with higher UFR/W were younger, with higher interdialytic weight gain and weight reduction percentage but lower dry, pre and post dialysis weight. Throughout the follow-up, 46 (21.4%) patients died, the majority over 70 years old, diabetic or with cardiovascular disease. There were neither differences regarding mortality between groups nor differences in UFR/W among patients who died and those who did not. Contrary to previous studies, we did not find an association between UFR/W and mortality, maybe due to a higher prevalence in the use of cardiovascular protection drugs and lower UFR/W.

**Conclusions:** The highest UFR/W were observed in younger patients with lower weight and were not associated with an increased mortality.

© 2021 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

DOI of original article:

<https://doi.org/10.1016/j.nefro.2020.10.007>.

<sup>☆</sup> Please cite this article as: Fernandez-Prado R, Peña-Esparragoza JK, Santos-Sánchez-Rey B, Pereira M, Avello A, Gomá-Garcés E, et al. Tasa de ultrafiltración horaria ajustada a peso corporal y mortalidad en hemodiálisis. Nefrología. 2021;41:426–435.

<sup>\*</sup> Corresponding author.

E-mail address: [raul.fernandezp@quironsalud.es](mailto:raul.fernandezp@quironsalud.es) (R. Fernandez-Prado).

2013-2514/© 2021 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Tasa de ultrafiltración horaria ajustada a peso corporal y mortalidad en hemodiálisis

### R E S U M E N

#### Palabras clave:

Hemodiálisis  
Mortalidad  
Tasa de ultrafiltración

**Antecedentes y objetivo:** La mortalidad de los pacientes en hemodiálisis es alta. Una tasa de ultrafiltración horaria ajustada por peso (UFR/W) elevada se ha asociado a episodios de hipotensión arterial y mayor riesgo de muerte y/o eventos cardiovasculares.

**Material y métodos:** Hemos evaluado la asociación entre UFR/W y mortalidad en 215 pacientes en hemodiálisis prevalentes seguidos durante  $28 \pm 6,12$  meses. Se estimaron características clínicas basales y UFR/W media a lo largo del seguimiento.

**Resultados:** La UFR/W media fue  $9,0 \pm 2,4$  y los terciles 7,1 y 10,1 mL/kg/h. Se categorizó a la población en función del tiempo que habían estado con UFR/W igual o superior a los puntos de corte descritos en la literatura como asociados a mayor mortalidad (10,0 mL/kg/h y 13,0 mL/kg/h). Los pacientes con mayor UFR/W fueron más jóvenes, con mayor ganancia de peso interdiálisis y porcentaje de reducción de peso, pero con menor peso seco, inicial y final. Durante el seguimiento, fallecieron 46 (21,4%) pacientes de los cuales la mayoría eran >70 años, diabéticos o con enfermedad cardiovascular. No hubo diferencias en mortalidad entre los grupos de UFR/W ni diferencias en la UFR/W entre los fallecidos y no fallecidos. En comparación con estudios previos donde describieron la asociación entre UFR/W y mortalidad, en nuestra población había más prevalencia de medicación protectora cardiovascular y no se observaron UFR/W tan altas.

**Conclusión:** En nuestro medio, la UFR/W más elevada se observó en pacientes más jóvenes y de menor peso y no se asoció a mayor mortalidad.

© 2021 Sociedad Española de Nefrología. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Introduction

Chronic kidney disease (CKD) is a health problem that in Spain affects more than 60,000 patients undergoing renal replacement therapy, including dialysis and kidney transplantation.<sup>1</sup> The survival of people with CKD, especially those on dialysis, is lower than that of the general population.<sup>2,3</sup> The main cause of the high mortality is the increased risk of cardiovascular disease,<sup>4,5</sup> which is due both to the high prevalence of classic cardiovascular risk factors (cardiovascular disease, hypertension, diabetes mellitus),<sup>6</sup> and to specific factors of uremia, known as emerging, among which are anemia,<sup>7</sup> bone mineral disease and loss of residual kidney function, as well as complications associated with factors of the dialysis technique itself, among which we find excessive ultrafiltration (UF) and intradialysis hypotension.<sup>8,9</sup>

The cardiovascular risk factors related to the hemodialysis technique itself are potentially modifiable. Although urea kinetics (KT/Vurea) is a marker of adequate dialysis, in some centers it conditions the duration of each therapy,<sup>10</sup> which could lead to short sessions if based only on this indicator. This model is common in the United States where by following a correct KT/Vurea, short dialysis sessions are frequent increasing cardiovascular risk,<sup>11</sup> among other reasons, short dialysis requires high hourly UFs that may increase the risk of hypotension.<sup>12</sup>

UF is a modifiable parameter and it has been described that it has a direct impact on the survival of the patient.<sup>13</sup> It is determined by the amount of fluid removed or ultrafiltered, and varies with the interdialytic weight gain (IWG) and the rapidity in which it is removed. A high hourly weight-adjusted ultrafiltration rate (UFR/W) increases the probability of arterial hypotension and the risk of cardiovascular mortality in conventional hemodialysis.<sup>14,15,16–18</sup> An increase in mortality has been described in patients with an hourly ultrafiltration ratio (UFR) of 6 mL/kg/h, and the increased mortality is being significant with UFR above 10 mL/kg/h.<sup>19</sup>

Episodes of hypotension intradialysis are associated with higher cardiovascular mortality,<sup>20</sup> arrhythmias, myocardial microinfarctions<sup>21</sup> which are the cause of “myocardial stunning”,<sup>22</sup> in addition to cerebral microinfarctions. The greater susceptibility to myocardial ischemia is due to the high prevalence of coronary atheromatosis and ventricu-

lar hypertrophy in these patients,<sup>23</sup> even in the absence of significant coronary lesion.<sup>24,25</sup> Hypotension is also associated with an increased risk of thrombosis of the vascular access.<sup>26</sup>

Presently, the UFR has been adjusted to the patient's weight, and it is expressed as mL/kg/h<sup>26</sup> and different studies have established a threshold of UFR/W of 10–13 mL/kg/h as the maximum rate, more fluid removal will require an increased in the duration of dialysis sessions, since above these limits there has been described an association with excess mortality.<sup>19,27,28</sup> However, many of these studies come from populations where the standards of health care (dialysis guidelines, access to health care and medication) or the characteristics of the population are not equivalent to Spain. Therefore, we have addressed the relationship between UFR/W and mortality in a dialysis unit in Spain.

## Methods

### Observational study

We conducted a prospective observational study in 215 prevalent hemodialysis patients at the Fundación Jiménez Díaz Hospital (FJD) and the Santa Engracia hemodialysis center. The study was presented in the FJD Ethics Committee, it complies with the Helsinki Declaration of Ethical Principles for Medical Research in Human Beings and the European Union Directive on Clinical Trials (2001/20/CE). The exclusion criteria were being on dialysis for less than three months and those receiving dialysis incremental hemodialysis. The data were collected between January 1, 2017 and June 30, 2019. At the beginning of the study, the following information was collected from the clinical history: (a) demographic: age, sex, hypertension, diabetes mellitus, peripheral vascular disease, heart failure and ischemic heart disease; (b) medication; (c) blood analytical data: albumin, total proteins, sodium, potassium and troponin I; (d) characteristics of dialysis at the beginning of the study and during the follow-up time collected through the Nefrosoft program: duration of the session, total weekly duration, dry weight (calculated by clinical assessment and bioimpedance, which was repeated monthly), IWG, total volume of UF, hourly UFR (mL/h) and adjusted by dry weight (UFR/W, mL/kg/h), percentage of weight reduction and total time on dialysis. Regarding the hemodialysis regimen, none of the patients

included in the study were on an incremental dialysis program, the percentage of online hemodialysis was 50%, and all individuals were treated with high-flow devices. Furthermore, the UF rates were constant throughout the session, without using automatic UF guidelines, thus maintaining a constant UF. UF profiles were used very rarely, as we preferred an increase in sessions or sodium profiles. Also, the type of vascular access, the characteristics of the dialysis bath (calcium and potassium), the blood pressure before and after hemodialysis, as well as the percentage of reduction in intradialysis blood pressure and the ventricular ejection fraction have been taken into account. left (LVEF). During the follow-up time, mortality and cause of death were recorded. Data on residual diuresis were not collected.

We analyzed the association between mortality and the mean UFR/W of all hemodialysis sessions during the study period. It was also evaluated whether  $\geq 25$  or  $\geq 50\%$  of sessions had  $\text{UFR/W} \geq 10$  and  $\geq 13$  mL/kg/h, since this is the maximum safe UFRs widely defined in the literature.<sup>19,27,28</sup> In our unit, the UF rate tend to be low, especially in those patients with reduced tolerance, who are usually those with a higher cardiovascular risk or more fragile. Thus, we increase the duration or the frequency of sessions which is an important difference with countries like the USA where dialysis is carried out in short times enough, to obtain sufficient KT/Vurea, without taking into account other factors. The economic aspects are fundamental, so unstable patients may have high UFs. This concept of individualization may reduce mortality.

### Literature analysis

In order to understand the divergence of the results obtained in this study with those published, we have compared the characteristics of the population studied with that of the two largest studies carried out in a western population that have provided the cut-off points generally used in literature.

### Statistical analysis

Quantitative variables were described by means and standard deviation or by median and interquartile range. The qualitative variables were defined by absolute and relative frequencies. To compare the different groups based on the UFR/W ranges and mortality, the Student's *t* test or the Mann-Whitney *U* test were used in the quantitative variables, and the *X*<sup>2</sup> test or Fisher's *F* in the quantitative variables. qualitative variables. In order to assess the ability of UFR/W values to discriminate between living and deceased patients, the receiver operating characteristic (ROC) curve and the area under it were obtained, along with its 95% confidence interval.

## Results

### Description of the population studied

The baseline characteristics of the 215 patients analyzed are represented in Table 1. This is a population with a majority of men, of a similar age to the mean of the Spanish dialysis population, with frequent comorbidity and use of diuretics in almost 30%. The mean UFR/W was  $9.0 \pm 2.4$  mL/kg/h and the tertiles 7.1 and 10.1 mL/kg/h.

### Characteristics of patients with elevated UFR/W

In Tables 2 and 3 shows the characteristics of the patients separated in different groups of UFR/W according to percentages of sessions with UFR/W greater than 10 or 13 mL/kg/h. Individuals with higher UFR/W were younger, with higher IWG, and had a higher percentage of weight reduction during dialysis, but with a lower initial and final dry weight. There were no variations in antihypertensive medication, anticoagulant use, time on dialysis, type of vascular access, or laboratory parameters. No significant differences were found in mortality between the groups analyzed.

### UFR/W and mortality

During the two and a half years of follow-up, 46 of the 215 patients (21.4%) died. The differences between the living and the deceased patients are shown in Table 4. There were no significant differences




Fig. 1 – ROC curve: UFR/W (mL/kg/h) and mortality.

in UFR/W between both groups. In a logistic regression model, analyzing mortality based on age and UFR/W, the association between age and mortality was statistically significant (OR 1.06 95% CI 1.03–1.09  $p < 0.001$ ). Given that the main cause of mortality in hemodialysis patients is cardiovascular, a sub-analysis of the 153 individuals with high baseline risk was performed by having one or more of the following characteristics: age  $> 70$  years, diabetes or cardiovascular disease (peripheral vascular disease, ischemic heart disease or heart failure) (Table 5). Among these patients, 41 (26.8%) died, while in the rest, mortality was 8%.

Finally, given that UFR/W is a continuous variable, we performed a ROC curve to determine the cut-off point for UFR/W that is associated with an increase in mortality in our population. However, the UFR/W did not predict mortality (area under the curve 0.509, 95% CI 0.415 to 0.602) (Fig. 1).

## Comparison with previous studies

Given that the results obtained on the relationship between UFR/W and mortality do not coincide with the previous reports in the literature, we analyzed whether there were differences in the characteristics of the different populations being evaluated.

Assimon et al.<sup>19</sup> concluded that a cut-off point of  $\text{UFR/W} > 13$  mL/kg/h is associated with higher mortality, despite the fact that, like us, they observed higher UFR/W in younger patients with lower weight. However, comparing our results with those of this study, we found that our patients with  $\text{UFR} > 13$  mL/kg/h in  $\geq 50\%$  of the sessions had lower dry weight (50.9 vs. 73.5 kg;  $p < 0.001$ ), lower IWG (2.61 vs. 3.6 kg;  $p = 0.001$ ) and a not so high mean UFR (13.41 mL/kg/h vs. 16.0 mL/kg/h;  $p < 0.001$ ). There were no differences regarding age or duration of the sessions (Table 6).

We also compare our results with those of Flythe et al.<sup>29</sup> and we observed that our patients had lower IWG (2.6 vs. 3.6 kg;  $p < 0.001$ ) and lower UFR (13.4 vs. 16.8 mL/kg/h;  $p < 0.001$ ) (Table 6).

Regarding the use of drugs, we compared our results with those of the Flythe study.<sup>29</sup> It is noteworthy that our patients, globally, have more use of beta-blockers, but this significant difference disappears in the group with  $\geq 50\%$  sessions with  $\text{UFR} > 13$  mL/kg/h, perhaps due to our low “n” value of 19 subjects. There are no differences in the use of angiotensin converting enzyme inhibitor/angiotensin II receptor antagonists (ACEI/ARA2) or calcium antagonists (Table 6). Our patients had a higher prevalence of cardioprotective medication, specifically beta-blockers, which reduce mortality on dialysis,<sup>30</sup> and improve the control of blood pressure: our mean systolic blood pressure (SBP) was  $144 \pm 19.3$  mmHg in the group of  $\geq 50\%$  of sessions with  $\text{UFR/W} > 13$  mL/kg/h, while in the other groups with higher UFR, 49.1% had SBP  $> 151$  mmHg and 40.9% had SBP  $> 160$  mmHg.<sup>19,29</sup>

**Table 1 – Baseline characteristics of the studied population.**

Patients (n = 215)			
Age (years)	67.1 ± 16.6	Dialysis: Total weekly duration (hours)	11.1 ± 1.4
Women, n (%)	71 (33%)	Total volume UF (mL)	2,276 ± 739
Hypertension, n (%)	194 (90.2%)	Hourly UFR (mL/h)	607 ± 175
Diabetes, n (%)	76 (35.3%)	UFR/W (mL/kg/h)	9.0 ± 2.44
Peripheral arterial disease, n (%)	60 (27.9%)	Pre-SBP (mmHg)	138 ± 17.4
Ischemic heart disease, n (%)	68 (31.6%)	Post-SBP (mmHg)	137 ± 20.2
Chronic heart failure, n (%)	53 (24.8%)	SBP reduction percentage	-0.5 ± 10.6
LVEF (%)	56.3 ± 10.6	<b>Time (vintage) on dialysis, n (%)</b>	
Left ventricular hypertrophy, n (%)	113 (54.1%)	<1 year	29 (13.5%)
Diastolic dysfunction, n (%)	136 (65.1%)	1–2 years	44 (20.5%)
Anticoagulation, n (%)	39 (18.7%)	2–3 years	35 (16.3%)
ACEI, n (%)	53 (24.7%)	3–4 years	18 (8.4%)
ARA2, n (%)	11 (5.1%)	>4 years	86 (40%)
Beta-blockers, n (%)	103 (47.9%)	<b>Vascular access, n (%)</b>	
Calcium antagonists, n (%)	96 (44.7%)	Native fistula	149 (72%)
Diuretics, n (%)	64 (29.9%)	Prosthetic fistula	28 (13.5%)
Alpha blockers, n (%)	40 (18.6%)	Central venous catheter	30 (14.5%)
Others, n (%)	9 (4.2%)	<b>Access thrombosis, n (%)</b>	42 (19.5%)
<b>Dialysis characteristics</b>		<b>Boo Biochemistry</b>	
Dry weight (kg)	68.9 ± 14.4	Albumin (g/dL)	3.80 ± 0.44
IWG (kg)	2.09 ± 1.87	Total proteins (g/dL)	6.63 ± 0.69
Initial weight HD (kg)	71.3 ± 15.7	Na (meq/L)	139 ± 3.19
Final weight HD (kg)	68.9 ± 14.7	K (meq/L)	5.00 ± 0.84
Weight reduction percentage	3.26 ± 3.35	Troponin I (ng/mL)	0.07 ± 0.24
Session duration (minutes)	216 ± 27	<b>Deceased, n (%)</b>	46 (21.4%)
<p>ARA2: angiotensin receptor 2 antagonists; LVEF, left ventricular ejection fraction; IWG: interdialysis weight gain; ACEI: angiotensin converting enzyme inhibitor; SBP: systolic blood pressure; Pre-SBP: predialysis SBP; Post-SBP: post-dialysis SBP; UF: ultrafiltration; UFR: hourly ultrafiltration; UFR/W: hourly ultrafiltration adjusted by weight. IWG and mean hourly UFR of all follow-up period; HD: hemodialysis.</p>			

## Discussion

In the present study, we did not find statistically significant differences in mortality in relation to the UFR/W. As expected, we observed an association between mortality and the presence of more and basic comorbidities. The with mortality is higher in older patients, patients with a history of ischemic heart disease and peripheral arterial disease, use of anticoagulants, a reduced LVEF, longer time of permanence in chronic hemodialysis, lower pre and post-dialysis SBP, poor nutritional status, lower weight, lower percentage weight reduction during dialysis and high potassium (Table 4).

High UFRs are often an obligatory consequence of high IWG and short hemodialysis sessions, with a relationship between high UFR and cardiovascular mortality.<sup>14–19</sup> By increasing the duration of hemodialysis sessions and decreasing the IWG, a reduction of UFRs could be achieved. Currently, strategies based on long dialysis sessions for better blood volume control have fallen into disuse in certain countries, although not in ours. Thus are remarkable results of the study by the group of Tassin in which, with long hemodialysis sessions (eight hours) achieve beneficial effects, accomplishing a tight control of blood volume, with reduced antihypertensive drugs and gradual reduction of body weight.<sup>31,32</sup> By increasing the time or frequency of hemodialysis sessions (dialysis doses), the aim is to reduce the risk of arterial hypotension. The most important determinant of intradialysis hypotension is the decrease in plasma volume below a critical threshold as a result of an imbalance between UF and refilling (vascular filling with water from the extravascular space).

Factors that predispose to intradialysis hypotension include diastolic dysfunction, atrial fibrillation, baroreceptor dysfunction, low sodium and calcium concentrations in the dialysate, high dialysate temperature, and hypotensive drugs, among others. The classic strategy to reduce the number of intradialysis hypotensive episodes is to adjust or decrease the UFR/W. UFR/W rates greater than 10 mL/kg/h are associated with an increased risk of intradialysis hypotension and mortality.<sup>33</sup> Some authors suggest that using low UFR/W (3–4 mL/kg/h) should allow a safe reduction in body weight and good blood pressure control even without drugs.<sup>34</sup> The UFR/W rate has been defined in different ways, which means that the results of the different stud-

ies cannot be extrapolated. Based on previous literature, a high UFR/W rate can be defined as the mean over a period or a percentage of sessions with a high UFR/W, usually greater than 10 mL/kg/h, as discussed below.

Among the main studies analyzing the relationship between mortality and UF are four observational studies. In the *Dialysis Outcomes and Practice Patterns Study* (DOPPS), Saran et al.<sup>33</sup> demonstrated an association between UFR/W > 10 mL/kg/h and total mortality (hazard ratio [HR] 1.09, p = 0.02) in 22,000 hemodialysis patients. In this study, longer sessions and higher Kt/Vurea were associated with lower mortality, while UFR/W > 10 mL/kg/h were associated with higher mortality. Hemodialysis sessions of more than 240 min were significantly associated with a lower relative risk (RR) of mortality (every 30 min of the hemodialysis session decreased the RR of mortality by 7%). Furthermore, they suggest that long hemodialysis sessions could reduce cardiovascular morbidity and mortality. In addition, Movilli et al.<sup>9</sup> conducted a prospective study in 287 hemodialysis patients, and described that survival decreases with high UF rates, especially with UFR/W greater than 12.4 mL/kg/h, for which they recommend increasing the time or frequency of hemodialysis sessions to avoid high UFR/W and improve survival. In a post hoc analysis of 1,846 patients from the HEMO study (*Hemodialysis Study*), Flythe et al.<sup>29</sup> found that UFR/W > 10 mL/kg/h were associated with an increase in cardiovascular and all-cause mortality, although this effect was more marked with UFR/W > 13 mL/kg/h (mortality of any cause HR 1.59, 95% CI 1.29–1.96; cardiovascular mortality HR 1.71, 95% CI 1.23–2.38). Furthermore, the work of Assimon et al.,<sup>19</sup> who analyzed UF in 118,394 hemodialysis patients in a retrospective cohort study, observed that UFR/W > 13 mL/kg/h during hemodialysis sessions of the first 30 days of follow-up was associated with higher mortality, and that an increase in UFR/W of 1 mL/kg/h was associated with an increased risk of death of 3%.

In our work, we studied the mean and the percentage of sessions that reached an excessive UF, defined as UFR/W > 10 mL/kg/h, during the 30 months of the study. Our mean total UFR/W was 9.0 mL/kg/h, but 59% (127) of the patients had a UFR/W > 10 mL/kg/h in more than 25% of the sessions and a 8.8% (19) had a UFR/W > 13 mL/kg/h in ≥50% of the dialysis sessions (Tables 2 and 3). Analysis of these data leads us to conclude that we could have increased the duration or frequency of hemodialysis sessions to avoid high rates of UF and improve sur-

**Table 2 – Baseline characteristics of the studied population as a function of UFR/W using the cut-off point of 10 mL/kg/h.**

	<25% UFR sessions ≥ 10 mL/kg/h (n = 88)	≥ 25% UFR sessions ≥ 10 mL/kg/h (n = 127)	p	<50% UFR sessions ≥ 10 mL/kg/h (n = 135)	≥ 50% UFR sessions ≥ 10 mL/kg/h (n = 80)	p
Age (years)	71.4 ± 13.6	64.2 ± 17.8	0.001	70.2 ± 15.0	62.0 ± 17.8	<0.001
Woman, n (%)	27 (30.7%)	44 (34.65%)	ns	46 (34.1%)	25 (31.2%)	ns
Hypertension, n (%)	80 (90.9%)	114 (89.8%)	ns	126 (93.3%)	68 (85.0%)	ns
Diabetes, n (%)	34 (38.6%)	42 (33.1%)	ns	50 (37.0%)	26 (32.5%)	ns
Peripheral arterial disease, n (%)	24 (27.3%)	36 (28.3%)	ns	38 (28.1%)	22 (27.5%)	ns
Ischemic heart disease, n (%)	33 (37.5%)	35 (27.6%)	ns	47 (34.8%)	21 (26.2%)	ns
Chronic heart failure, n (%)	22 (25.3%)	31 (24.4%)	ns	35 (26.1%)	18 (22.5%)	ns
LVEF (%)	55.5 ± 10.3	56.8 ± 10.8	0.001	56.2 ± 10.6	56.5 ± 10.8	ns
Left ventricular hypertrophy, n (%)	47 (54.7%)	66 (53.7%)	ns	76 (57.6%)	37 (48.1%)	ns
Diastolic dysfunction, n (%)	62 (72.1%)	74 (60.2%)	ns	95 (72.0%)	41 (53.2%)	ns
<b>Dialysis characteristics</b>						
Dry weight (kg)	75.5 ± 14.8	64.4 ± 12.2	<0.001	72.6 ± 14.6	62.7 ± 11.8	<0.001
IWG (kg)	1.75 ± 0.99	2.32 ± 2.26	0.01	1.81 ± 0.95	2.55 ± 2.74	0
Initial weight HD (kg)	77.7 ± 17.6	66.8 ± 12.6	<0.001	74.6 ± 16.6	65.6 ± 12.3	<0.001
Final weight HD (kg)	75.3 ± 15.4	64.4 ± 12.3	<0.001	72.4 ± 14.9	62.8 ± 12.1	<0.001
Weight reduction percentage	2.67 ± 3.66	3.66 ± 3.06	0.04	2.68 ± 2.98	4.25 ± 3.72	0
Session duration (minutes)	221 ± 25	217 ± 28	ns	220 ± 26	216 ± 28	ns
Total weekly duration (hours)	11.1 ± 1.27	11.1 ± 1.49	ns	11.1 ± 1.32	11.1 ± 1.54	ns
Total volume UF (mL)	1,953 ± 732	2,500 ± 659	<0.001	2,041 ± 708	2,680 ± 608	<0.001
Hourly UFR (ml/h)	514 ± 175	671 ± 142	<0.001	542 ± 166	718 ± 127	<0.001
UFR/W (ml/Kg/h)	6.77 ± 1.5	10.55 ± 1.62	<0.001	7.57 ± 1.67	11.42 ± 1.41	<0.001
PreSBP (mmHg)	137 ± 18.1	139 ± 17.0	ns	137 ± 17.5	140 ± 17.3	ns
Post-SBP (mmHg)	135 ± 20.9	138 ± 19.6	ns	135 ± 20.3	140 ± 19.9	ns
SBP reduction percentage	-0.9 ± 12.4	-0.23 ± 9.17	ns	-0.8 ± 11.7	0.03 ± 8.44	ns
Deceased, n (%)	15 (17%)	31 (24.4%)	ns	30 (22.2%)	16 (20%)	ns

LVEF, left ventricular ejection fraction; IWG: interdialysis weight gain; HD: hemodialysis; ns: not significant; SBP: systolic blood pressure; Pre-SBP: predialysis SBP; Post-SBP: post-dialysis SBP; UF: ultrafiltration; UFR: hourly ultrafiltration ratio; UFR/W: hourly ultrafiltration adjusted by weight.

**Table 3 – Baseline characteristics of the studied population as a function of UFR/W using the cut-off point of 13 mL/kg/h.**

	<25% UFR sessions ≥13 mL/kg/h (n = 172)	≥25% UFR sessions ≥13 mL/kg/h (n = 43)	p	<50% UFR sessions ≥13 mL/kg/h (n = 196)	≥50% UFR sessions ≥13 mL/kg/h (n = 19)	p
Age (years)	68.3 ± 16.3	60.3 ± 16.6	0.011	70.5 ± 25.2	56.0 ± 15.0	0.017
Woman, n (%)	118 (68.6%)	26 (60.5%)	ns	63 (32.1%)	8 (42.1%)	ns
Hypertension, n (%)	156 (90.7%)	38 (88.4%)	ns	177 (90.3%)	17 (89.5%)	ns
Diabetes, n (%)	60 (34.9%)	16 (37.2%)	ns	67 (32.7%)	9 (47.4%)	ns
Peripheral arterial disease, n (%)	48 (27.9%)	12 (27.9%)	ns	54 (27.6%)	6 (31.6%)	ns
Ischemic heart disease, n (%)	57 (33.1%)	11 (25.6%)	ns	64 (32.7%)	4 (21.1%)	ns
Chronic heart failure, n (%)	44 (25.7%)	9 (20.9%)	ns	49 (25.1%)	4 (21.1%)	ns
LVEF (%)	56.2 ± 10.4	56.8 ± 11.8	ns	60 ± 5	60 ± 10	ns
Left ventricular hypertrophy, n (%)	92 (54.8%)	21 (51.2%)	ns	103 (54.2%)	10 (52.6%)	ns
Diastolic dysfunction, n (%)	117 (69.6%)	19 (46.3%)	0.009	127 (66.8%)	9 (47.4%)	ns
<b>Dialysis characteristics</b>						
Dry weight (kg)	72.0 ± 13.8	56.8 ± 9.32	<0.001	69.0 ± 18.7	50.9 ± 13.8	<0.001
IWG (kg)	2.08 ± 1.60	2.10 ± 2.69	ns	1.97 ± 1.00	2.61 ± 1.06	0.008
Initial weight HD (kg)	74.1 ± 15.7	60.3 ± 10.2	<0.001	70.7 ± 19.7	56.3 ± 15.2	<0.001
Final weight HD (kg)	71.9 ± 14.2	57.1 ± 9.7	<0.001	68.7 ± 19.1	51.4 ± 14.3	<0.001
Weight reduction percentage	2.80 ± 2.68	5.06 ± 4.84	0.005	2.67 ± 1.30	4.35 ± 0.58	<0.001
Session duration (minutes)	221 ± 26	211 ± 27	0.026	220 ± 26	208 ± 28	ns
Total weekly duration (hours)	11.2 ± 1.33	10.8 ± 1.65	ns	12.0 ± 1.50	10.5 ± 2.62	0.05
Total UF volume (mL)	2,170 ± 724	2,690 ± 651	<0.001	2,214 ± 722	2,888 ± 631	<0.001
Hourly UFR (ml/h)	576 ± 172	726 ± 131	<0.001	593 ± 175	743 ± 104	<0.001
UFR/W (mL/kg/h)	8.15 ± 1.87	12.41 ± 1.16	<0.001	8.58 ± 2.1	13.41 ± 0.86	<0.001
Pre-SBP (mmHg)	137 ± 17.0	140 ± 19.3	ns	137 ± 17.2	144 ± 19.3	ns
Post-SBP (mmHg)	136 ± 19.8	141 ± 21.5	ns	137 ± 23.2	153 ± 17.5	0.002
SBP reduction percentage	-0.8 ± 11.1	0.67 ± 8.70	ns	-0.48 ± 11.1	1.79 ± 11.6	ns
Deceased, n (%)	35 (20.3%)	11 (25.6%)	ns	42 (21.4%)	4 (21.1%)	ns

LVEF, left ventricular ejection fraction; IWG: interdialysis weight gain; HD: hemodialysis; ns: not significant; SBP: systolic blood pressure; Pre-SBP: predialysis SBP; Post-SBP: post-dialysis SBP UF: ultrafiltration; UFR: hourly ultrafiltration ratio; UFR/W: hourly ultrafiltration adjusted by weight.

Table 4 – Comparison between alive and deceased patients.

	Alive (n = 169)	Deceased (n = 46)	p		Alive (n = 169)	Deceased (n = 46)	p
Age (years)	64.5 ± 16.7	77.0 ± 11.4	<0.001	Session duration (minutes)	219 ± 26	215 ± 28	ns
Women, n (%)	55 (32.5%)	16 (34.8%)	ns	Total weekly duration (hours)	11.08 ± 1.35	11.13 ± 1.6	ns
Hypertension, n (%)	152 (89.9%)	42 (91.3%)	ns	Total volume UF (mL)	2,315 ± 744	2,127 ± 709	ns
Diabetes, n (%)	57 (33.7%)	19 (41.3%)	ns	Hourly UF (mL/h)	611 ± 174	592 ± 178	ns
Peripheral arterial disease, n (%)	40 (23.7%)	20 (43.55)	0.013	UFR/W (mL/kg/h)	8.99 ± 2.42	9.03 ± 2.54	ns
Ischemic heart disease, n (%)	44 (26%)	24 (52.2%)	0.001	Pre-SBP (mmHg)	139 ± 16.8	133 ± 19.0	0.036
Chronic heart failure, n (%)	41 (24.4%)	12 (26.1%)	ns	Post-SBP (mmHg)	139 ± 20.0	130 ± 19.6	0.01
LVEF (%)	57.7 ± 9.01	50.9 ± 14.2	0.005	% reduction in SBP	-0.12 ± 10.8	-2.0 ± 9.8	ns
Left ventricular hypertrophy, n (%)	89 (53.6%)	24 (55.8%)	ns	<b>Time (vintage) on dialysis, n (%)</b>			<0.001
Diastolic dysfunction, n (%)	103 (62.0%)	33 (76.7%)	ns	<1 year	27 (16.2%)	2 (4.4%)	
Anticoagulation, n (%)	24 (14.5%)	15 (34.1%)	0.006	1–2 years	40 (24%)	4 (8.9%)	
ACEI, n (%)	44 (26%)	9 (19.6%)	ns	2–3 years	32 (19.2%)	3 (6.7%)	
ARA2, n (%)	9 (5.3%)	2 (4.3%)	ns	3–4 years	6 (3.6%)	12 (26.7%)	
Beta-blockers, n (%)	79 (47.7%)	24 (52.2%)	ns	> 4 years	62 (37.1%)	24 (53.3%)	
Calcium antagonists, n (%)	81 (47.9%)	15 (32.6%)	ns	<b>Vascular access, n (%)</b>			0.003
Diuretics, n (%)	53 (31.5%)	11 (23.9%)	ns	Native fistula	127 (77.4%)	22 (51.2%)	
Alpha blockers, n (%)	36 (21.3%)	4 (8.7%)	ns	Prosthetic fistula	18 (11.0%)	10 (23.3%)	
Others, n (%)	8 (4.7%)	1 (2.2%)	ns	Central venous catheter	19 (11.6%)	11 (25.6%)	
<b>Dialysis characteristics</b>				<b>Blood Biochemistr</b>			
Dry weight (kg)	70.0 ± 14.6	65.0 ± 12.9	0.039	Albumin (g/dL)	3.85 ± 0.43	3.60 ± 0.40	<0.001
IWG (kg)	2.09 ± 1.01	2.06 ± 3.54	ns	Total proteins (g/dL)	6.71 ± 0.67	6.35 ± 0.71	0.001
Initial weight HD (kg)	72.6 ± 15.9	66.3 ± 14.3	0.019	Na (meq/L)	139 ± 3.16	139 ± 3.34	ns
Final weight HD (kg)	70.0 ± 14.7	64.5 ± 13.9	0.027	K (meq/L)	4.93 ± 0.80	5.24 ± 0.93	0.026
Weight reduction percentage	3.40 ± 3.72	2.72 ± 0.93	0.037	Troponin I (ng/mL)	0.08 ± 0.28	0.06 ± 0.04	ns

ARA2: angiotensin receptor 2 antagonists; LVEF, left ventricular ejection fraction; IWG: interdialysis weight gain; HD: hemodialysis; ACEI: angiotensin converting enzyme inhibitor; ns: not significant; SBP: systolic blood pressure; Pre-SBP: predialysis SBP; Post-SBP: post-dialysis SBP; UF: ultrafiltration; UFR: hourly ultrafiltration ratio; UFR/W: hourly ultrafiltration adjusted by weight.

**Table 5 – Characteristics of the high-risk subgroup: patients aged >70 years and/or type 2 diabetes mellitus and/or cardiovascular disease (peripheral vascular disease, ischemic heart disease, or heart failure).**

Subanalysis (n = 153)			
Age (years)	73.3 ± 14.1	Final weight HD (kg)	68.6 ± 14.1
Woman, n (%)	43 (28.1%)	Weight reduction percentage	3.07 ± 2.69
Hypertension, n (%)	144 (94.1%)	Session duration (minutes)	216 ± 27.6
Diabetes, n (%)	76 (49.7%)	Total weekly duration (hours)	11.0 ± 1.39
Peripheral arterial disease, n (%)	60 (39.2%)	Total volume UF (mL)	2,216 ± 714
Ischemic heart disease, n (%)	68 (44.4%)	Hourly UFR (mL/h)	597 ± 172
Chronic heart failure, n (%)	53 (34.9%)	UFR/W (mL/kg/h)	9.23 ± 3.27
LVEF (%)	54.6 ± 11.7	Pre-SBP (mmHg)	138 ± 18.2
Left ventricular hypertrophy, n (%)	82 (55.0%)	Post-SBP (mmHg)	138 ± 18.1
Diastolic dysfunction, n (%)	105 (70.5%)	SBP reduction percentage	−0.08 ± 8.56
Anticoagulation, n (%)	33 (22.1%)	<b>Vascular access, n (%)</b>	
ACEI, n (%)	41 (26.8%)	Native fistula	104 (69.8%)
ARA2, n (%)	7 (4.6%)	Prosthetic fistula	20 (13.4%)
Beta-blockers, n (%)	87 (56.9%)	Central venous catheter	25 (16.8%)
Calcium antagonists, n (%)	62 (40.5%)	<b>Blood Biochemistry</b>	
Diuretics, n (%)	47 (30.9%)	Albumin (g/dL)	3.81 ± 0.39
Alpha blockers, n (%)	21 (13.7%)	Total proteins (g/dL)	6.62 ± 0.66
Others, n (%)	5 (3.3%)	Na (meq/L)	139 ± 3.35
<b>Dialysis characteristics</b>		K (meq/L)	5.07 ± 0.83
Dry weight (kg)	68.6 ± 13.8	Troponin I (ng/mL)	0.04 (0.05)
IWG (kg)	2.11 ± 2.15	<b>Deceased, n (%)</b>	41 (26.8%)
Initial weight HD (kg)	70.8 ± 14.6		

ARA2: angiotensin receptor 2 antagonists; LVEF, left ventricular ejection fraction; IWG: interdialysis weight gain; HD: hemodialysis; ACEI: angiotensin converting enzyme inhibitor; SBP: systolic blood pressure; Pre-SBP: predialysis SBP; Post-SBP: post-dialysis SBP; UF: ultrafiltration; UFR: hourly ultrafiltration ratio; UFR/W: hourly ultrafiltration adjusted by weight.

vival. This data allows to estimate that, by adjusting the UFR in each session for each patient according to their dry weight, IWG and baseline comorbidities, the potential individual risk associated with the most demanding UFR/W could be reduced. In our sample, patients with higher UFR/W were younger, with lower dry weight, higher IWG, lower initial and final weight, higher UF volume and greater percentage of weight reduction in hemodialysis. The characteristics of this population with higher UFR/W may have influenced the low mortality observed since, even when analyzing separately the group with the highest cardiovascular risk and the oldest, we did not notice statistically significant differences. However, we cannot rule out that they may suffer imperceptible damage that increases mortality in a long follow-up. The high UFR/W in patients with lower dry weight are explained by the fact that, in these people, small IWG in absolute values (kg) represent important increases in blood volume with respect to weight and lead to higher UFR/W. To avoid high UFR/W in patients with lower dry weight, it would be necessary to consider increasing the time and/or frequency of hemodialysis sessions.

Probably, the small sample size of our study compared to that of Assimon (19 patients vs. 21,735 with UFR/W > 13 mL/kg/h) represents an important limitation. Mortality may not have statistical significance in our group with the highest UFR/W because, being people with less weight (dry weight 51.4 kg) and younger, they have a lower cardiovascular risk compared to the American population studied by Assimon, which had a dry weight 22.1 kg higher than ours. As compared to the Assimon study, our patients with a higher UFR/W had a lower IWG and, therefore, a lower UFR/W. This is compounded by a probable lower cardiovascular risk due to being underweight and younger than the individuals in the Assimon study. We consider that this may be the explanation why this group, despite having UFR/W > 13 mL/kg/h in ≥50% of hemodialysis sessions, was not associated with a significant increase in mortality. Our mean follow-up was 2.3 years, this is like in the Assimon study, but it would be interesting to analyze the data regarding mortality in the longer term. Contrasting our results with those of the Assimon and Flythe studies, we found that individuals with higher UFR/W are, in general, younger in all three studies. However, even the highest mean UFR/W and IWG (13.41 mL/kg/h and 2.61 kg) in our patients are lower than those of the other two studies, a fact that we consider has significantly influenced the results of our study, since people with higher UFR/W did not have a significant

increase in mortality during the period of follow-up. The differences related to weight and age are probably related to the demographic and socioeconomic characteristics of the different populations, especially weight, given the higher prevalence of obesity in the United States.

An elevated UFR/W promotes the development of intradialysis hypotension, loss of residual renal function, ischemic damage, and possible vascular access thrombosis. In addition, high UFR/W contributes to maintain appropriate euolemia, which is associated with favorable cardiovascular outcomes, including the improvement in left ventricular hypertrophy<sup>35</sup> and prevention of heart failure decompensations, with a better survival.<sup>36–39</sup> Therefore, it is important to implement individualized strategies in order to guarantee a specific UFR/W for the hemodynamic and cardiovascular situation of each patient, but not exceeding 13 mL/kg/h.

Intradialysis echocardiographic assessment and measurement of the changes in troponin induced by hypotension have shown that cardiac ischemia is a potential mediator of mortality related with UF.<sup>40</sup> Excessive UFR/W should be avoided to allow appropriate refilling in each patient, for which different solutions are proposed. Daugirdas has analyzed how UFR in hemodialysis could be optimized<sup>41</sup> and suggests that it might be more appropriate to scale UFR rates in relation to body surface area rather than body weight. Another alternative would be to calculate the “ideal” dry weight of the patient by bioimpedance, and made an individual adjustment of the UFR.<sup>42</sup> Other authors are performing UF profiles to assess whether UFR can be intensified at the beginning of the hemodialysis session.<sup>43</sup>

In conclusion, in the patient population of our dialysis unit, probably representative of Spanish, it was not observed a relationship between UFR/W and mortality. These results differ from those reported in the literature. The differences could be explained by a better baseline situation of the patients with the highest UFR/W, as well as differences in the baseline characteristics of the population and the magnitude of the UFR/W versus previous studies that did associate UFR/W with mortality. Obese patients on hemodialysis (HD) tend to have lower mortality due to the reverse epidemiology, while the thinner patients may be malnourished. This means that, possibly, extreme weights have to be eliminated from the analysis, since they may aggravate or reduce mortality. Obese people will have a lower rate of UF per weight and it also protects them from mortality. In the United States, obese patients are frequent and they may have an impact on the results. Thus, in



**Table 6 – Main studies on the association between UFR/W and mortality in hemodialysis.**

	Assimon	Flythe Global group	Our study	Comparisons with	
				Assimon	Flythe
Mean follow-up (years)	2.3	6.6	2.3		
n	118,394	1,846	215		
Age (years)	61 ± 15	57.6 ± 14	67.1 ± 16.6	<0.001	<0.001
Diabetes,%	52.1%	44.6%	35.3%	<0.001	<0.001
UFR/W (mL/kg/h)	9.4 ± 4.3	12.1 ± 4.6	9.0 ± 2.44	0.017	<0.001
Dry weight (kg)	79.2 ± 22.4	No data	68.9 ± 14.4	<0.001	
IWG (kg)	2.9 ± 2.2	2.9 ± 1.1	2.09 ± 1.87	<0.001	<0.001
Session duration (minutes)	218 ± 36	218 ± 24	216 ± 27	ns	ns
ACEI/ARB2, n (%)	No data	484 (26.2%)	63 (29.3%)		ns
Beta-blockers, n (%)	No data	553 (30.0%)	103 (47.9%)		<0.001
Calcium antagonists, n (%)	No data	910 (49.3%)	96 (44.7%)		ns
	UFR/W 10–13 mL/kg/h	UFR/W 10–13 mL/kg/h	≥50% sessions		UFR/W > 10 mL/kg/h
n	26,794 (22.6%)	517 (28.0%)	80 (37.2%)		
Age (years)	61 ± 15	57.9 ± 13.5	62 ± 17.8	ns	ns
Diabetes,%	54.0%	46.8%	0.325	<0.001	0.023
UFR/W (mL/kg/h)	11.4 ± 0.9	11.4 ± 8.6	11.42 ± 1.41	ns	ns
Dry weight (kg)	75.6 ± 18.3	No data	62.7 ± 11.8	<0.001	
IWG (kg)	3.3 ± 2.0	3.0 ± 0.9	2.55 ± 2.74	0.004	ns
Session duration (minutes)	214 ± 28	220 ± 23	216 ± 28	ns	ns
ACEI/ARB2, n (%)	No data	124 (24.0%)	28 (35.0%)		0.049
Beta-blockers, n (%)	No data	151 (29.2%)	36 (45.0%)		0.006
Calcium antagonists, n (%)	No data	247 (47.8%)	41 (51.2%)		ns
	UFR/W > 13 mL/kg/h	UFR/W > 13 mL/kg/h	≥50% sessions		UFR/W > 13 mL/kg/h
n	21,735 (18.4%)	685 (37.1%)	19 (8.8%)		
Age (years)	58 ± 16	54.8 ± 14.7	56.0 ± 15.0	ns	ns
Diabetes,%	51.4%	42.5%	0.474	ns	ns
UFR/W (mL/kg/h)	16.0 ± 2.9	16.8 ± 3.6	13.41 ± 0.86	<0.001	<0.001
Dry weight (kg)	73.5 ± 6.5	No data	50.9 ± 13.8	<0.001	
IWG (kg)	3.6 ± 2.2	3.6 ± 1	2.61 ± 1.06	0.001	<0.001
Session duration (minutes)	205 ± 28	209 ± 23	208 ± 28	ns	ns
ACEI/ARB2, n (%)	No data	208 (30.4%)	7 (36.8%)		ns
Beta-blockers, n (%)	No data	222 (32.4%)	9 (47.7%)		ns
Calcium antagonists, n (%)	No data	371 (54.2%)	12 (63.2%)		ns

ARA2: angiotensin receptor 2 antagonists; IWG: interdialytic weight gain; ACEI: angiotensin converting enzyme inhibitor; ns: not significant; UFR/W: hourly ultrafiltration adjusted by weight.

our population of patients with an appropriate pharmacological protection of cardiovascular system and in which the upper extremes of UFR/W are avoided, we did not observe a negative impact of UFR/W on mortality. Another possible explanation for not finding differences in mortality between the groups, may be a greater care for more vulnerable patients, who would be treated with longer dialysis and a lower rate of UF/hour/weight, in an attempt to improve tolerance; this strategy would approximate their mortality to that of the healthier group. Given that the sample size was relatively small, it would be interesting to propose a Spanish multicenter study to establish cut-off points for UFR/W of increased risk of death adapted to the Spanish reality.

## Financing

Project financed by the health research fund ISC-III and co-financed with FEDER funds PI16/01298.

## Conflict of interests

The authors have no conflicts of interest to declare.

## REFERENCES

1. Registro Español de Enfermedades Renales (REER). <http://www.registrorenal.es>.
2. Weiner DE. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. *J Am Soc Nephrol.* 2004;15:1307–15.
3. Naylor KL, Kim SJ, McArthur E, Garg AX, McCallum MK, Knoll GA. Mortality in incident maintenance dialysis patients versus incident solid organ cancer patients: a population-based cohort. *Am J Kidney Dis.* 2019;73:765–76.
4. Ahmadmehrabi S, Tang WHW. Hemodialysis-induced cardiovascular disease. *Semin Dial.* 2018;31:258–67.
5. Hill NR, Fatoba ST, Oke JL, Hirst JA, O'Callaghan CA, Lasserson DS, et al. Global prevalence of chronic kidney disease – a systematic review and meta-analysis. *PLoS One.* 2016;11:e0158765.
6. Safar ME, London GM, Plante GE. Arterial stiffness and kidney function hypertension. *Hypertension.* 2004;43:163–8.
7. Robinson BM, Joffe MM, Berns JS, Pisoni RL, Port FK, Feldman HI. Anemia and mortality in hemodialysis patients: accounting for morbidity and treatment variables updated over time. *Kidney Int.* 2005;68:2323–30.
8. Wang M, Obi Y, Streja E, Rhee CM, Lau WL, Chen J, et al. Association of parameters of mineral bone disorder with mortality in patients on hemodialysis according to level of residual kidney function. *Clin J Am Soc Nephrol.* 2017;12:1118–27.

9. Movilli E, Gaggia P, Zubani R, Camerini C, Vizzardi V, Parrinello G, et al. Association between high ultrafiltration rates and mortality in uraemic patients on regular haemodialysis. A 5-year prospective observational multicentre study. *Nephrol Dial Transplant*. 2007;22:3547–52.
10. Perl J, Dember LM, Bargman JM, Browne T, Charytan DM, Flythe JE, et al. The use of a multidimensional measure of dialysis adequacy—moving beyond small solute kinetics. *Clin J Am Soc Nephrol*. 2017;12: 839–47.
11. Sarafidis P, Faitatzidou D, Papagianni A. Benefits and risks of frequent or longer haemodialysis: weighing the evidence. *Nephrol Dial Transplant*. 2020.
12. Pirkle JL, Comeau ME, Langefeld CD, Russell GB, Balderston SS, Freedman BI, et al. Effects of weight-based ultrafiltration rate limits on intradialytic hypotension in hemodialysis. *Hemodial Int*. 2018;22:270–8.
13. Lee Y-J, Okuda Y, Sy J, Lee YK, Obi Y, Cho S, et al. Ultrafiltration rate, residual kidney function, and survival among patients treated with reduced-frequency hemodialysis. *Am J Kidney Dis*. 2020;75:342–50.
14. Shoji T, Tsubakihara Y, Fujii M, Imai E. Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. *Kidney Int*. 2004;66:1212–20.
15. Tisler A, Akocsi K, Borbas B, Fazakas L, Ferenczi S, Gorogh S, et al. The effect of frequent or occasional dialysis-associated hypotension on survival of patients on maintenance haemodialysis. *Nephrol Dial Transplant*. 2003;18:2601–5.
16. Okamoto K, Kobayashi S, Noiri E. Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the Dialysis Outcomes and Practice Patterns Study. *Kidney Int*. 2006;70:1877.
17. Kalantar-Zadeh K, Regidor DL, Kovesdy CP, Van Wyck D, Bunnapradist S, Horwich TB, et al. Fluid retention is associated with cardiovascular mortality in patients undergoing long-term hemodialysis. *Circulation*. 2009;119:671–9.
18. Brunelli SM, Chertow GM, Ankers ED, Lowrie EG, Thadhani R. Shorter dialysis times are associated with higher mortality among incident hemodialysis patients. *Kidney Int*. 2010;77:630–6.
19. Assimon MM, Wenger JB, Wang L, Flythe JE. Ultrafiltration rate and mortality in maintenance hemodialysis patients. *Am J Kidney Dis*. 2016;68:911–22.
20. Cheung AK, Sarnak MJ, Yan G, Berkoben M, Heyka R, Kaufman A, et al. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. *Kidney Int*. 2004;65:2380–9.
21. Stefánsson BV, Brunelli SM, Cabrera C, Rosenbaum D, Anum E, Ramakrishnan K, et al. Intradialytic hypotension and risk of cardiovascular disease. *Clin J Am Soc Nephrol*. 2014;9:2124–32.
22. Jefferies HJ, Virk B, Schiller B, Moran J, McIntyre CW. Frequent hemodialysis schedules are associated with reduced levels of dialysis-induced cardiac injury (myocardial stunning). *Clin J Am Soc Nephrol*. 2011;6:1326–32.
23. Bos WJW, Bruin S, van Olden RW, Keur I, Wesseling KH, Westerhof N, et al. Cardiac and hemodynamic effects of hemodialysis and ultrafiltration. *Am J Kidney Dis*. 2000;35:819–26.
24. Tok D, Gullu H, Erdogan D, Topcu S, Ciftci O, Yildirim I, et al. Impaired coronary flow reserve in hemodialysis patients: a transthoracic doppler echocardiographic study. *Nephron Clin Pract*. 2005;101:c200–6.
25. Toyoda K. Simultaneous onset of haemorrhagic and ischaemic strokes in a haemodialysis patient. *J Neurol Neurosurg Psychiatry*. 2002;72:673–4.
26. Chang TI, Paik J, Greene T, Desai M, Bech F, Cheung AK, et al. Intradialytic hypotension and vascular access thrombosis. *J Am Soc Nephrol*. 2011;22:1526–33.
27. Kuipers J, Verboom LM, Ipema KJR, Paans W, Krijnen WP, Gaillard CAJM, et al. The prevalence of intradialytic hypotension in patients on conventional hemodialysis: a systematic review with meta-analysis. *Am J Nephrol*. 2019;49:497–506.
28. European Best Practice Guidelines Expert Group on Hemodialysis, European Renal Association. Section II. Haemodialysis adequacy. *Nephrol Dial Transplant*. 2002;17:16–31.
29. Flythe JE, Kimmel SE, Brunelli SM. Rapid fluid removal during dialysis is associated with cardiovascular morbidity and mortality. *Kidney Int*. 2011;79:250–7.
30. Agarwal R, Sinha AD, Pappas MK, Abraham TN, Tegegne GG. Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial. *Nephrol Dial Transplant*. 2014;29:672–81.
31. Laurent G, Charra B. The results of an 8 h thrice weekly haemodialysis schedule. *Nephrol Dial Transplant*. 1998;13:125–31.
32. Chazot C, Vo-Van C, Deleaval P, Lorriaux C, Hurot JM, Mayor B, et al. Predialysis systolic blood pressure evolution in incident hemodialysis patients: effects of the dry weight method and prognostic value. *Blood Purif*. 2012;33:275–83.
33. Saran R, Bragg-Gresham JL, Levin NW, Twardowski ZJ, Wizemann V, Saito A, et al. Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPS. *Kidney Int*. 2006;69:1222–8.
34. Ok E, Levin NW, Ascì G, Chazot C, Toz H, Ozkahya M. Interplay of volume, blood pressure, organ ischemia, residual renal function, and diet: certainties and uncertainties with dialytic management. *Semin Dial*. 2017;30:420–9.
35. Daugirdas JT. Intradialytic hypotension and splanchnic shifting: Integrating an overlooked mechanism with the detection of ischemia-related signals during hemodialysis. *Semin Dial*. 2019;32:243–7.
36. Ozkahya M, Ok E, Toz H, Ascì G, Duman S, Basci A, et al. Long-term survival rates in haemodialysis patients treated with strict volume control. *Nephrol Dial Transplant*. 2006;21:3506–13.
37. Wizemann V, Wabel P, Chamney P, Zaluska W, Moissl U, Rode C, et al. The mortality risk of overhydration in haemodialysis patients. *Nephrol Dial Transplant*. 2009;24:1574–9.
38. Gunal AI, Kirciman E, Guler M, Yavuzkir M, Celiker H. Should the preservation of residual renal function cost volume overload and its consequence left ventricular hypertrophy in new hemodialysis patients? *Renal Fail*. 2004;26:405–9.
39. Ozkaya M, Ok E, Cirit M, Aydin S, Akçiçek F, Başçı A, et al. Regression of left ventricular hypertrophy in haemodialysis patients by ultrafiltration and reduced salt intake without antihypertensive drugs. *Nephrol Dial Transplant*. 1998;13:1489–93.
40. Burton JO, Jefferies HJ, Selby NM, McIntyre CW. Hemodialysis-induced cardiac injury: determinants and associated outcomes. *Clin J Am Soc Nephrol*. 2009;4:914–20.
41. Daugirdas JT, Schneditz D. Hemodialysis ultrafiltration rate targets should be scaled to body surface area rather than to body weight. *Semin Dial*. 2017;30:15–9.
42. Delano M, Sodini C. Evaluating calf bioimpedance measurements for fluid overload management in a controlled environment. *Physiol Meas*. 2018;39:125009.
43. Tugman MJ, Narendra JH, Li Q, Wang Y, Hinderliter AL, Brunelli SM, et al. Ultrafiltration-profiled hemodialysis to reduce dialysis-related cardiovascular stress: study protocol for a randomized controlled trial. *Contemp Clin Trials Commun*. 2019;15:100415.